Debiasing hazard-based, time-varying vaccine effects using vaccine-irrelevant infections: An observational extension of a pivotal Phase 3 COVID-19 vaccine efficacy trial

TL;DR

This paper introduces a method leveraging vaccine-irrelevant infections as negative controls to accurately estimate time-varying vaccine effectiveness, addressing biases in traditional Cox regression analyses in observational COVID-19 vaccine studies.

Contribution

It develops a novel bias mitigation approach using vaccine-irrelevant infections to identify causal, hazard-based, time-varying vaccine effects in observational data.

Findings

Supported that the Moderna booster is more effective and durable against Omicron than Cox regression suggested.

Demonstrated the utility of negative controls in reducing bias in vaccine effectiveness estimation.

Provided estimators and assumptions for causal inference in observational vaccine studies.

Abstract

Understanding how vaccine effectiveness (VE) changes over time can provide evidence-based guidance for public health decision making. While commonly reported by practitioners, time-varying VE estimates obtained using Cox regression are vul- nerable to hidden biases. To address these limitations, we describe how to leverage vaccine-irrelevant infections to identify hazard-based, time-varying VE in the pres- ence of unmeasured confounding and selection bias. We articulate assumptions under which our approach identifies a causal effect of an intervention deferring vaccination and interaction with the community in which infections circulate. We develop sieve and efficient influence curve-based estimators and discuss imposing monotone shape constraints and estimating VE against multiple variants. As a case study, we examine the observational booster phase of the Coronavirus Vaccine Efficacy (COVE) trial of the Moderna mRNA-1273 COVID-19 vaccine which used symptom-triggered multi- plex PCR testing to identify acute respiratory illnesses (ARIs) caused by SARS-CoV-2 and 20 off-target pathogens previously identified as compelling negative controls for COVID-19. Accounting for vaccine-irrelevant ARIs supported that the mRNA-1273 booster was more effective and durable against Omicron COVID-19 than suggested by Cox regression. Our work offers an approach to mitigate bias in hazard-based, time- varying treatment effects in randomized and non-randomized studies using negative controls.